

Design, synthesis and DNA-cleaving efficiency of photoswitchable dimeric azobenzene-based C_2 -symmetric enediynes†

Amit Basak,* Debarati Mitra, Moumita Kar and Kumar Biradha

Received (in Cambridge, UK) 30th January 2008, Accepted 28th March 2008

First published as an Advance Article on the web 25th April 2008

DOI: 10.1039/b801644e

Designed azobenzene-based enediyne-amino acid C_2 -symmetric hybrids have been synthesized and the role of amino acid linker in stabilizing the *Z* form has been demonstrated; DNA-binding and cleavage studies have established higher reactivity of the *Z*-isomers.

Symmetry plays an important role in many chemical and biological processes.^{1,2} Many key proteins and enzymes exist as homo dimers with two-fold axis of symmetry namely the C_2 -symmetry. These are biologically active only in this homo dimeric form.^{3–5} Various research groups have designed C_2 -symmetric DNA-cleaving agents⁶ and studied their cleavage efficiency.⁷ Enediynes have now been established as a fertile ground for designing novel DNA-cleaving agents.⁸ Although many reports of ingenious design of enediynes are there in the literature,⁹ including from our own laboratory,¹⁰ as such there is no report of how the biological activity of enediynes depends upon their symmetry property. In order to study such effects, we have designed novel hybrid molecules consisting of azo benzene,¹¹ enediyne and amino acid. These molecules have different symmetry groups in the *E* and *Z* forms. Their synthesis and chemical as well as biological reactivities are reported herein which nicely demonstrated the importance of geometric considerations while designing new enediynes. Since C_2 -symmetry is our prime consideration, two types of molecules **Type I** and **Type II** were targeted (Fig. 1). Both the types consisted of azobenzene, enediyne and amino acid which are joined by two carbon linkers. Use of same amino acid in **Type I** systems retains the C_2 while incorporation of dissimilar amino acids or same amino acid with different configuration in **Type II** molecules breaks the C_2 -symmetry. The latter molecules were synthesized for comparing the activity of the C_2 and non- C_2 symmetric molecules. The actual target molecules belonging to different classes are shown in Fig. 1. We wanted to address the following question: can perturbation of symmetry element affect the DNA-cleaving potential of enediyne?

We first carried out the MM2 calculation to find out the energy-minimized conformation of **Type I** molecules **1a** and **2a**. The exercise revealed a crescent shape conformation for the *Z*-isomer, while the *E*-isomer has a zigzag conformation.

Bioorganic Laboratory, Department of Chemistry, Indian Institute of Technology, Kharagpur, India. E-mail: abask@chem.iitkgp.ernet.in; Fax: +91 3222 282252; Tel: +91 322 283300

† Electronic supplementary information (ESI) available: ¹H, ¹³C NMR of new compounds, VT NMR, details of MM2 and DNA-binding and cleavage studies. CCDC 676458. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/b801644e

The complementarity of conformation between the *Z*-isomer and the helical shape of DNA may ensure higher binding with *ds*-DNA and hence higher cleaving efficiency. The stability imparted by the π -stacking interaction¹² between the benzene rings of the phenylalanine-based system is expected to slow down the kinetics of thermal *Z* to *E* re-isomerisation. It is interesting to note that the energy minimization of the *Z*-form of the non C_2 -symmetric molecule **2e** containing D- and L-phenylalanine showed very little π -stacking interactions in the *Z*-isomer. For **2d**, the isopropyl group of valine lies away from the phenyl group.

The synthetic endeavour towards **1a/1b** started with the preparation of the azobenzene-amino acid diesters **3a/3b**. These were hydrolysed to the free acids **4a/4b**. The corresponding dipotassium salts **5a/5c** were esterified with 2-bromoacetylamine **6** in DMF.¹³ The target molecules **1a/1b** were isolated pure in 85% yield after column purification (Si-gel, DCM : MeOH = 30 : 1). The corresponding aliphatic system **1c** was also prepared *via* a similar route (Scheme 1). The synthesis of **Type II** molecules was similarly carried out. The structures of all the compounds were in agreement with ¹H, ¹³C NMR as well as mass spectral data (HRMS).

The configuration around the N–N double bond was first determined by recording the UV spectrum in CH₃CN. For the *trans* compounds a strong λ_{max} at 363 nm appeared typical of the *trans* azobenzenes.¹⁴ For the *cis* isomers a characteristic λ_{max} at higher wavelength of 440 nm was observed. The






Fig. 1 Structures of target enediynes.



The reactivity of the enediynes towards Bergman cyclization (BC)¹⁵ as studied by differential scanning calorimetry (DSC)¹⁶ indicated similar onset temperatures (80–90 °C) for the aromatic enediynes which is very similar to what was observed for isolated enediynyl amides.¹³ The solution phase kinetics performed on **1a** did show slow BC kinetics at 45 °C with a half life of 7 days. For the non-aromatic enediyne, the *E* isomer **1c** showed an onset temperature of 50 °C for BC while in solution



For the non-benzenoid enediynes **1c**/**2c**, the gel pattern after 2 h clearly indicated higher cleaving potency for the *Z*-isomer (~30%) as compared to the *E*-isomer. However, with time, as more and more *Z* form is converted to the *E*-isomer, the extent of cleavage became almost the same. The other interesting and highly important observation is the generation of linear DNA (form III) for the aliphatic enediynes; the *Z*-form showing generation of form III after 2 h of incubation at 20 °C while at 37 °C both *E* and *Z* forms showed linear cuts. It is possible that the linear cut observed for the *E*-isomer is due to the presence of the *Z*-form (~15%) under equilibrating

Compound	$t_{1/2}(20\text{ }^{\circ}\text{C})/\text{h}$	Compound	$t_{1/2}(20\text{ }^{\circ}\text{C})/\text{h}$
2a	30.0	2d	12.0
2b	19.0	2e	19.0
2c	7.2	10	2.3




Fig. 3 pBR322 DNA cleavage experiment of compounds **1a–1e/2a–2e**; For A–H: lane 1: control DNA in TAE buffer (pH 8, 7 μ L) + CH_3CN (5 μ L); lane 2: DNA in TAE buffer (pH 8, 7 μ L) + *E* isomer (0.02 mM) in CH_3CN (5 μ L); lane 3: DNA in TAE buffer (pH 8, 7 μ L) + *Z*-isomer (0.02 mM) in CH_3CN (5 μ L).

conditions. It may be noted that the isolated non-benzenoid enediyne **8** is a much inferior cleaving agent as compared to **1c/2c**; the extent of cleavage even after 12 h incubation was much less (only 50% as compared to 85%). It also failed to show formation of any linear form under similar conditions.¹⁷ The non- C_2 -symmetric molecules **1d/2d** and **1e/2e** have been found to be very poor DNA-cleavers. All these point to the importance of having an azobenzene endowed with C_2 -symmetry in the design.

The DNA-binding studies by absorption titrations involving addition of a solution of calf thymus DNA to a fixed concentration of the probe¹⁸ indicated higher degree of hypochromism¹⁹ for the *Z*-isomer **2a** as compared to **1a**. The binding constant (using the Benesi–Hildebrand equation) revealed greater binding affinity for enediyne **2a** ($2.5\times$ as compared to **1a**). Thus the higher DNA-cleavage efficiency for the *Z*-isomer is correlated to its binding efficiency.

Thus, we have successfully designed and synthesized azobenzene-based enediyne–amino acid C_2 -symmetric hybrids. A new way of modulating the biological activity of this class of molecules by introducing a symmetry element like C_2 has been firmly established. Future research will concentrate on exploit-

ing this idea to generate water-soluble cytotoxic agents. Since *E* to *Z* isomerization is done photochemically, our work opens up the possibility of enhancing the DNA-cleaving efficiency of the C_2 -symmetric enediynes *via* photoirradiation.

A. B. thanks DST, Government of India for a research grant. D. M. and M. K. are grateful to CSIR, Government of India for a senior research fellowship. We are also grateful to Prof. A. K. Ghosh and Prof. A. K. Das, Biotechnology Department for their help in densitometric measurements and MM2 calculations. The Department of Science and Technology, Govt. of India, is thanked for the CCD-X-ray (under FIST) and 400 MHz NMR facilities (under IRPHA).

Notes and references

1. J. Nicolle, *Science*, 1965, **38**, 38.
2. D. Lucet, T. Le Gall and C. Mioskowski, *Angew. Chem., Int. Ed.*, 1998, **37**, 2580.
3. J. W. Mellons, *Nat. Med.*, 1996, **2**, 274.
4. C. Kessler and V. Mamta, *Gene*, 1990, **92**, 1.
5. R. Marmorstein, M. Carey, M. Plastin and S. C. Harrison, *Nature*, 1992, **356**, 408.
6. D. Ranganathan, R. K. Mishra, B. K. Patel and N. K. Vaish, *Proc. Indian Acad. Sci.*, 1994, **106**, 1071.
7. (a) S. A. Strobel and P. B. Dervan, *Science*, 1990, **249**, 73; (b) D. R. Corey, D. Pei and P. G. Schultz, *Biochemistry*, 1990, **28**, 8277; (c) M. V. Keck and S. J. Lippard, *J. Am. Chem. Soc.*, 1992, **114**, 3386; (d) A. Sitalni, E. C. Long, A. M. Pyle and J. K. Barton, *J. Am. Chem. Soc.*, 1992, **114**, 2303.
8. (a) A. Basak, S. M. Mandal and S. S. Bag, *Chem. Rev.*, 2003, **103**, 4077; (b) M. E. Maier, F. Boße and A. J. Niestroj, *Eur. J. Org. Chem.*, 1999, **1**; (c) K. C. Nicolaou and A. L. Smith, *Modern Acetylene Chemistry*, ed. P. J. Stang and F. Diederich, VCH, Weinheim, 1995, p. 203.
9. (a) K. C. Nicolaou and W. M. Dai, *Angew. Chem., Int. Ed. Engl.*, 1991, **30**, 1387; (b) B. König, *Eur. J. Org. Chem.*, 2000, 381; (c) H. Lhermite and D. Grierson, *Contemp. Org. Synth.*, 1996, **3**, 93; (d) D. S. Rawat and J. M. Zaleski, *Synlett*, 2004, 393.
10. M. Kar and A. Basak, *Chem. Rev.*, 2007, **14**, 2861.
11. (a) S. Shinkai, T. Minami, Y. Kasano and O. Manabe, *J. Am. Chem. Soc.*, 1983, **105**, 1851; (b) A. Srivastava, S. Ghorai, S. A. Bhattacharya and S. Bhattacharya, *J. Org. Chem.*, 2005, **70**, 6574.
12. W. Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag, New York, 1984, p. 261.
13. A. Basak, S. Mandal, A. K. Das and V. Bertolasi, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 873.
14. M. Bose, D. Groff, J. Xie, E. Brustad and P. G. Schultz, *J. Am. Chem. Soc.*, 2006, **128**, 388.
15. R. G. Bergman, *Acc. Chem. Res.*, 1973, **6**, 25.
16. (a) R. H. Grubbs and D. Kratz, *Chem. Ber.*, 1993, **126**, 149; (b) B. König and H. Rütters, *Tetrahedron Lett.*, 1994, **35**, 3501.
17. (a) A. Basak, H. M. Bdour, J. C. Shain, S. Mandal, K. Rudra and S. Nag, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 4354; (b) A. Basak, U. K. Khamrai and J. C. Shain, *Tetrahedron Lett.*, 1997, **38**, 6067.
18. S. S. Mandal, U. Varshney and S. Bhattacharya, *Bioconjugate Chem.*, 1997, **8**, 798.
19. A. M. Pyle, J. P. Rehmann, R. Meshoyrer, C. V. Kumar, N. J. Turro and J. K. Barton, *J. Am. Chem. Soc.*, 1989, **111**, 3051.